eligibility_summary
Inclusion: ≥18, confirmed metastatic/unresectable gastric/GEJ adenocarcinoma progressed after standard therapy, measurable disease, ECOG 0–2, life ≥3 mo, prior AEs ≤G1, tumor tissue available. Exclusion: prior trastuzumab/PD‑1 toxicity stop, pregnancy/lactation, CNS mets, <3 y other cancer, autoimmune disease, immunodeficiency/HIV/transplant, major CV disease, recent RT/surgery/trial/other therapy, systemic steroids/immunosuppressants, active HBV/HCV, cytopenias, hepatic/renal dysfunction or other safety risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06098898 tests NK510 adoptive cell therapy (intravenous infusions of activated natural killer cells) alone or combined with monoclonal antibodies in advanced gastric cancer. Drugs/interventions and mechanisms: 1) NK510 (cell therapy): NK cells kill tumor via innate cytotoxicity (perforin/granzyme) and antibody‑dependent cellular cytotoxicity (ADCC via CD16) when paired with mAbs. 2) Tislelizumab (anti‑PD‑1 mAb) or atezolizumab (anti‑PD‑L1 mAb): checkpoint inhibitors that block PD‑1/PD‑L1 to reinvigorate T and NK cell activity. 3) Trastuzumab (anti‑HER2 mAb): binds HER2 to inhibit signaling and promotes ADCC by NK cells. Targets/cells/pathways: NK effector cells, PD‑1/PD‑L1 checkpoint pathway, HER2 (ERBB2) on tumor cells, FcγRIIIa (CD16)-mediated ADCC axis. Patients are biopsied for PD‑L1 and HER2 to guide combinations. Early phase, dose‑escalation.